Literature DB >> 820246

Antimicrobial susceptibility testing of six clinical isolates of Aspergillus.

M Kitahara, V K Seth, G Medoff, G S Kobayashi.   

Abstract

Several different methods of performing susceptibility tests on six clinical isolates of Aspergillus are described. Some of the conditions that affected the level of susceptibility to drugs were: the type of media used, temperature and time of incubation, and the initial inoculum size. For amphotericin B susceptibility testing, the effectiveness of the polyene antibiotic as measured by visual growth was equivalent to the effectiveness as measured by inhibition of ribonucleic acid synthesis and dry-weight increase. For 5-fluorocytosine and rifampin, the visual-turbidity method gave minimum inhibitory concentrations that were much higher than those determined by effects on ribonucleic acid synthesis and dry weight. The reason for these discrepancies in susceptibility testing with 5-fluorocytosine and rifampin are unknown. We conclude that the most relevant test of this fungus to antifungal agents will have to be determined by the correlation of in vitro data with animal experiments and clinical results.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 820246      PMCID: PMC429649          DOI: 10.1128/AAC.9.6.908

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  TREATMENT OF PULMONARY ASPERGILLOMA WITH AMPHOTERICIN B.

Authors:  H IKEMOTO
Journal:  Arch Intern Med       Date:  1965-05

2.  Growth of the yeastlike phase of Histoplasma capsulatum in a fluid medium.

Authors:  S B SALVIN
Journal:  J Bacteriol       Date:  1950-02       Impact factor: 3.490

3.  Characterization of the binding of amphotericin B to Saccharomyces cerevisiae and relationship to the antifungal effects.

Authors:  J Kotler-Brajtburg; G Medoff; D Schlessinger; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1974-12       Impact factor: 5.191

4.  RNA metabolism during morphogenesis in Histoplasma capsulatum.

Authors:  S S Cheung; G S Kobayashi; D Schlessinger; G Medoff
Journal:  J Gen Microbiol       Date:  1974-06

5.  Cure of Aspergillus ustus endocarditis on a prosthetic valve.

Authors:  J Carrizosa; M E Levison; T Lawrence; D Kaye
Journal:  Arch Intern Med       Date:  1974-03

6.  Rapid radiometric method of testing susceptibility of mycobacteria and slow-growing fungi to antimicrobial agents.

Authors:  P Benitez; G Medoff; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1974-07       Impact factor: 5.191

7.  Rifampin: inhibition of ribonucleic acid synthesis after potentiation by amphotericin B in Saccharomyces cerevisiae.

Authors:  E Battaner; B V Kumar
Journal:  Antimicrob Agents Chemother       Date:  1974-04       Impact factor: 5.191

8.  In vitro antifungal activity of clotrimazole (Bay b 5097).

Authors:  S Shadomy
Journal:  Infect Immun       Date:  1971-08       Impact factor: 3.441

9.  In vitro susceptibility of isolates of Aspergillus fumigatus and Sporothrix schenckii to amphotericin B.

Authors:  J W Brandsberg; M E French
Journal:  Antimicrob Agents Chemother       Date:  1972-11       Impact factor: 5.191

View more
  14 in total

1.  Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: analysis by site of isolation.

Authors:  J Guinea; T Peláez; L Alcalá; M J Ruiz-Serrano; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

2.  Potentiation of antifungal activity of amphotericin B by azithromycin against Aspergillus species.

Authors:  M H Nguyen; C J Clancy; Y C Yu; A S Lewin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-11       Impact factor: 3.267

3.  Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole.

Authors:  A Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Standardization of a hyphal inoculum of aspergilli for amphotericin B susceptibility testing.

Authors:  V Bezjak
Journal:  J Clin Microbiol       Date:  1985-04       Impact factor: 5.948

5.  Rapid and highly reproducible method for antifungal susceptibility testing of Aspergillus species.

Authors:  H Yamada; S Kohno; S Maesaki; H Koga; M Kaku; K Hara; H Tanaka
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

6.  Inhibition of RNA synthesis as a therapeutic strategy against Aspergillus and Fusarium: demonstration of in vitro synergy between rifabutin and amphotericin B.

Authors:  C J Clancy; Y C Yu; A Lewin; M H Nguyen
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

7.  Therapy of murine aspergillosis with amphotericin B in combination with rifampin of 5-fluorocytosine.

Authors:  J Arroyo; G Medoff; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

8.  Activity of amphotericin B, 5-fluorocytosine, and rifampin against six clinical isolates of Aspergillus.

Authors:  M Kitahara; V K Seth; G Medoff; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

9.  Susceptibility testing of filamentous fungi to amphotericin B by a rapid radiometric method.

Authors:  W G Merz; D Fay; B Thumar; D Dixon
Journal:  J Clin Microbiol       Date:  1984-01       Impact factor: 5.948

10.  Minimal inhibitory concentrations of lucknomycin, a new polyenic derivative, for Candida and Aspergillus spp.

Authors:  J Martínez-Quesada; J M Torres-Rodriguez; M Rosés-Codinachs; M Amaral-Olivera
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.